Loading...
Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)
Zhong, J. Brown, S. Serra, Maria Shuttleworth, P. Bownes, P. Thompson, C. Reed, Rachel Reeves, Kimberley Dubec, Michael McHugh, Damien
Zhong, J.
Brown, S.
Serra, Maria
Shuttleworth, P.
Bownes, P.
Thompson, C.
Reed, Rachel
Reeves, Kimberley
Dubec, Michael
McHugh, Damien
Citations
Altmetric:
Abstract
Introduction: Radiotherapy is the most common curative treatment for non-metastatic prostate cancer; however, up to 13% of patients will develop local recurrence within 10 years. Patients can undergo further and potentially curative treatment including salvage surgery, brachytherapy (BT), external beam radiotherapy, high-intensity focused ultrasound and cryotherapy. Systematic review shows that high-dose-rate (HDR) BT and stereotactic body radiotherapy (SBRT) have the best outcomes in terms of biochemical control and lowest side effects. The reirradiation options for previously irradiated prostate cancer (RO-PIP) trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage HDR-BT or SBRT and provide prospective data on patient recorded toxicity outcomes that will inform a future phase III trial.
Methods and analysis: The primary endpoint of the RO-PIP feasibility study is to evaluate the patient recruitment potential over 2 years to a trial randomising to either SBRT or HDR-BT for patients who develop local recurrence of prostate cancer following previous radiation therapy. The aim is to recruit 60 patients across 3 sites over 2 years and randomise 1:1 to SBRT or HDR-BT. Secondary objectives include recording clinician and patient-reported outcome measures to evaluate treatment-related toxicity. In addition, the study aims to identify potential imaging, genomic and proteomic biomarkers that are predictive of toxicity and outcome based on hypoxia status, a prognostic marker of prostate cancer.
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Article
Citation
Zhong J, Brown S, Serra M, Shuttleworth P, Bownes P, Thompson C, et al. Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT). BMJ open. 2022 Nov 8;12(11):e068580. PubMed PMID: 36351720. Epub 2022/11/10. eng.